Price History

Hover for the daily close. The dotted line marks the period open.

Compare SLDB with… →

SLDB Key Statistics

As of Sep 4, 2026

Trading

Open: $10.20
Previous Close: $10.42
Day's Range: 10.20–10.48
52-Week Range: 3.79–11.45
Volume: 495.30K
Beta: 2.44

Valuation

Market Cap: $1.10B
P/E Ratio: unprofitable
EPS (ttm): −1.89

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$174.33M
Profit margin: 0.00%
Shares Outstanding: 107.23M
1-Year Return: +84.35%

Dividend and dates

Earnings Date: November 2, 2026estimated
Avg Volume: 1.60M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SLDB Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−83.40%+81.74%

201820192020202120222023202420252026*

Year	Return
2026 (partial year)	+81.74%
2025	+41.00%
2024	−34.85%
2023	+14.13%
2022	−79.50%
2021	−76.91%
2020	+70.34%
2019	−83.40%
2018	+18.48%

As of September 4, 2026.

SLDB Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$174.33M	—
2024	$0.00	−$124.70M	—
2023	$0.00	−$96.02M	—
2022	$8.09M	−$85.98M	−1062.3%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$179.21M	−$174.33M	—
2024	$0.00	—	−$129.73M	−$124.70M	—
2023	$0.00	—	−$104.32M	−$96.02M	—
2022	$8.09M	—	−$99.27M	−$85.98M	−1062.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SLDB Valuation vs Biotechnology Median

Median of 656 stocks

Metric	SLDB	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Solid Biosciences Inc. (SLDB) carries a market capitalisation of $1.10B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 121.

Over the past 52 weeks the price has ranged from $3.79 to $11.45. The most recent close on file for SLDB is $10.25, dated September 4, 2026. That is −$0.17 (−1.63%) against the previous close. The latest close sits 170.45% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $174.33M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −1.89.

Across the 4 fiscal years on file, revenue moves from $8.09M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The trailing one-year price return is +84.35%. Across 5 years the annualized return works out at −24.58%. Beta against the wider market is reported at 2.44. Daily returns over the trailing 8 years annualize to a volatility of 105.84%.

Growth & Income

No dividend is on file for SLDB.

So far in 2026 the price is +81.74%. Across the complete calendar years on file, 2020 returned +70.34% and 2019 returned −83.40%. Of the 8 complete calendar years on file, 4 finished higher.

Peer Comparison

Solid Biosciences Inc. (SLDB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Solid Biosciences Inc.	SLDB	$1.10B	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Solid Biosciences Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Solid Biosciences Inc.

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Visit website →

Solid Biosciences Inc. (SLDB) Stock Analysis